Niagen Bioscience Q1 net sales $31.5M (+3% YoY); net income $6.3M up from $5.1M

Niagen Bioscience, Inc.

2026-Q1 EPS reported $0.07 revenue$31,474,000

Gross margin 63.5%; adjusted EBITDA $3.8M vs $4.9M year ago.
Launched clinician-directed telehealth platform Niagen Plus and first cruise ship clinic partnership.
Completed divestiture of Analytical Reference Standards segment to LGC Standards in Feb 2026.
Board approved $20M share repurchase program; repurchased $2.4M in Q1.
FY 2026 G&A outlook improved to +$3-4M vs prior +$4-5M; sales & marketing investment to rise.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Niagen Bioscience, Inc. reported first quarter of 2026 results: revenue $31.5 million, net income $6.3 million, EPS $0.08 and $0.07, respectively. Guidance reaffirmed.

Period: first quarter of 2026
Revenue: $31.5 million
Net income: $6.3 million
EPS: $0.08 and $0.07, respectively
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results Net sales increased to $31.5 million Gross margin improved to 63.5% Net income of $6.3 million, up $1.3 million from the prior year and adjusted EBITDA of $3.8 million LOS ANGELES, CA - May 6, 2026 - Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2026.

View on SEC.gov

Browse all earnings releases →

Niagen Bioscience, Inc. filing history →

Source: SEC EDGAR

accession 0001386570-26-000031

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.